Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

doi:10.1056/NEJMoa1613627

Clinical Trial

. 2017 Mar 23;376(12):1131-1140.

doi: 10.1056/NEJMoa1613627.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Hilary Longhurst¹, Marco Cicardi¹, Timothy Craig¹, Konrad Bork¹, Clive Grattan¹, James Baker¹, Huamin H Li¹, Avner Reshef¹, James Bonner¹, Jonathan A Bernstein¹, John Anderson¹, William R Lumry¹, Henriette Farkas¹, Constance H Katelaris¹, Gordon L Sussman¹, Joshua Jacobs¹, Marc Riedl¹, Michael E Manning¹, Jacques Hebert¹, Paul K Keith¹, Shmuel Kivity¹, Sergio Neri¹, Donald S Levy¹, Maria L Baeza¹, Robert Nathan¹, Lawrence B Schwartz¹, Teresa Caballero¹, William Yang¹, Ioana Crisan¹, María D Hernandez¹, Iftikhar Hussain¹, Michael Tarzi¹, Bruce Ritchie¹, Pavlina Králíčková¹, Mar Guilarte¹, Syed M Rehman¹, Aleena Banerji¹, Richard G Gower¹, Debra Bensen-Kennedy¹, Jonathan Edelman¹, Henrike Feuersenger¹, John-Philip Lawo¹, Thomas Machnig¹, Dipti Pawaskar¹, Ingo Pragst¹, Bruce L Zuraw¹; COMPACT Investigators

Collaborators, Affiliations

Collaborators

COMPACT Investigators:
B Frankum, P Burton, F Perram, K Bennett, K Keat, G Levi, W Gould, P Ferrie, S Waserman, A Crawley, S Santucci, J O’Quinn, S Claude, L Potvin, A Perron, M Ouellet, R Gagnon, J Skripitsky, R Doepker, J Jabs, I Krcmova, I Tepla, R Martincova, M Novosadova, R Vojtechova, J Hanzlikova, R Matouskova, M Vachova, M Dockal, L Varga, N Veszeli, G Temesszentandrási, K V Kőhalmi, L Egri, B Csonka, J Bali, I Leibovich, R Ofir, M Kidon-Yankovich, S Fridland, A Merlinsky, V Leibo, D Dror, L Kadar, S Benor, S Beer, R Labrisch, M Yehuda, E Bonanni, M Wu, A Zanichelli, M Mansi, F Sechi, A Rizzotto, F Giardino, D Maiorca, F Fidone, M Amico-Roxas, M Varga, M Iftene, E Buzdugan, I D Badiu-Tisa, A Pop, A Sala, P Suné, V Cardona, N Moreno, M Labrador, P Gómez Salcedo, R Cabañas, M Pedrosa, D Rivero-Paparoni, P Palao-Ocharán, C Gómez-Traseira, A Alvez, E Phillips, A Borobia, A Prieto, M Angel Conejo, A Mur, J M Zubeldia, M Tordera, E Ibanez, E Gimeno, M Flowerdew, A Frew, K Davies, K Nambiar, R Rye, D Lambert, R Chowdhry, R Varghese, A Murray, L S Robinson, C McPherson, A Beddoe, R Sarpong, A Kieliszkowska, S Grigoriadou, M-J Valda, G Boyapati, A Zdanaviciene, D Andrews, J Laffan, I Nasr, A Bellin, B Crone, C Evans, A Twumasi, C Mende, S Cleary, M Stanton, C Schaeffer, G Ghaffari, F Ishmael, E Rael, N Vernon, N Kalra, J Zaragoza-Buxo, V Reddy, L Buyantseva, A Fazzi, H Heisey, J A Brown, A Kane, M Sweigart, T Johnson, L Kosh, S Shaikh, M Scarupa, A Economides, M White, M Kaliner, S Persons, A Newman, M J Noonan, A Johnson, J Tucker, D Aguilar, K Murphy, B Berendts, K Klefas, S Merritt, P Bak, R Chambers, M Iandoli, M Canova, S Bednar, J Vetrano, M Crawford, S Poston, D Paige, K Fuqua, K Hale, H Combs, H Haggard, K Phillipson, W Soong, M Sikora, M Lemke, P Luthin, C Neal, E Gilbert, K Bradley, W Zhao, M Abdalgani, A M Irani, B Ward, A Perry, A Hill, S Twombly, C Witte, J Rud, S Levitch, T Vonasek, J Curl, K Silva, T Mostofi, C Doss, N Schultz, D McNeil, A Thornton, A Urbank, P Rancitelli, N Palecek, T Singletary, J Altman, E Soltero, K Soltero, D F Soteres, L M Webb, D K Walters, J A Allen, G N Salem, E De La Cruz, A Hafez, T J Tyma, L Endean, A Tolman, M Naggs, A Davis, J Nelson, M Parks, B Borts, J Blair, J Sun, Y Brown, B Daly, C Tanguilig, T Le, M Tutto, M Berg, M LeFebvre, M Mallari

Affiliation

¹ From Barts Health NHS Trust (H.L.) and St. John's Institute of Dermatology, Guy's Hospital (C.G.), London, and the Clinical Investigation and Research Unit, Royal Sussex County Hospital, Brighton (M.T.) - all in the United Kingdom; Ospedale Luigi Sacco-U.O. Medicina Generale, Milan (M.C.), and the Department of Internal Medicine, University of Catania, Catania (S.N.) - both in Italy; Department of Medicine and Pediatrics, Penn State Hershey Allergy, Asthma, and Immunology, Hershey (T. Craig), and CSL Behring, King of Prussia (D.B.-K., J.E., D.P.) - both in Pennsylvania; the Department of Dermatology, Johannes Gutenberg University Mainz, Mainz (K.B.), and CSL Behring, Marburg (H. Feuersenger, J.-P.L., T.M., I.P.) - both in Germany; Baker Allergy, Asthma and Dermatology Research Center, Portland, OR (J. Baker); Institute for Asthma and Allergy, Chevy Chase, MD (H.H.L.); Allergy and Immunology Unit, Chaim Sheba Medical Center, Tel Hashomer (A.R.), and Allergy and Immunology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv (S.K.) - both in Israel; Clinical Research Center of Alabama, Birmingham (J. Bonner, J.A.); Department of Internal Medicine, Allergy Section Cincinnati, University of Cincinnati College of Medicine, Cincinnati (J.A.B.), and Toledo Institute of Clinical Research, Toledo (S.M.R.) - both in Ohio; Allergy Asthma Research Associates Research Center, Dallas (W.R.L.); Hungarian Angioedema Center, Third Department of Internal Medicine, Semmelweis University, Budapest (H. Farkas); the Department of Medicine, Immunology, and Allergy, Campbelltown Hospital, Campbelltown, NSW, Australia (C.H.K.); the Department of Clinical Immunology and Allergy, St. Michael's Hospital, Toronto (G.L.S.), Centre de Recherche Appliqué en Allergie de Québec, Quebec, QC (J.H.), McMaster University, Hamilton, ON (P.K.K.), Ottawa Allergy Research and University of Ottawa Medical School, Ottawa (W.Y.), and University of Alberta Hospital, Edmonton (B.R.) - all in Canada; Allergy and Asthma Clinical Research, Walnut Creek (J.J.), University of California, San Diego School of Medicine, La Jolla (M.R., B.L.Z.), and 705 W. La Veta Ave., Suite 101, Orange (D.S.L.) - all in California; Medical Research of Arizona, Scottsdale (M.E.M.); Hospital General Universitario Gregorio Marañón and Biomedical Research Network on Rare Diseases-U761, Institute for Health Research, Gregorio Marañón (M.L.B.), and the Allergy Department, Hospital La Paz Institute for Health Research, Biomedical Research Network on Rare Diseases (T. Caballero), Madrid, the Allergy Department, IIS Hospital Universitario La Fe, Valencia (M.D.H.), and Hospital Universitario Vall d'Hebron, Barcelona (M.G.) - all in Spain; Asthma and Allergy Association, Colorado Springs, CO (R.N.); Department of Internal Medicine, Virginia Commonwealth University, Richmond (L.B.S.); Spitalul Clinic Municipal, Cluj-Napoca, Romania (I.C.); Vital Prospects Clinical Research Institute, Tulsa, OK (I.H.); Institute of Clinical Immunology and Allergology, University Hospital, Hradec Kralove, Czech Republic (P.K.); Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston (A.B.); and Marycliff Allergy Specialists, Spokane, WA (R.G.G.).

PMID: 28328347
DOI: 10.1056/NEJMoa1613627

Free article

Clinical Trial

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Hilary Longhurst et al. N Engl J Med. 2017.

Free article

. 2017 Mar 23;376(12):1131-1140.

doi: 10.1056/NEJMoa1613627.

Authors

Collaborators

COMPACT Investigators:
B Frankum, P Burton, F Perram, K Bennett, K Keat, G Levi, W Gould, P Ferrie, S Waserman, A Crawley, S Santucci, J O’Quinn, S Claude, L Potvin, A Perron, M Ouellet, R Gagnon, J Skripitsky, R Doepker, J Jabs, I Krcmova, I Tepla, R Martincova, M Novosadova, R Vojtechova, J Hanzlikova, R Matouskova, M Vachova, M Dockal, L Varga, N Veszeli, G Temesszentandrási, K V Kőhalmi, L Egri, B Csonka, J Bali, I Leibovich, R Ofir, M Kidon-Yankovich, S Fridland, A Merlinsky, V Leibo, D Dror, L Kadar, S Benor, S Beer, R Labrisch, M Yehuda, E Bonanni, M Wu, A Zanichelli, M Mansi, F Sechi, A Rizzotto, F Giardino, D Maiorca, F Fidone, M Amico-Roxas, M Varga, M Iftene, E Buzdugan, I D Badiu-Tisa, A Pop, A Sala, P Suné, V Cardona, N Moreno, M Labrador, P Gómez Salcedo, R Cabañas, M Pedrosa, D Rivero-Paparoni, P Palao-Ocharán, C Gómez-Traseira, A Alvez, E Phillips, A Borobia, A Prieto, M Angel Conejo, A Mur, J M Zubeldia, M Tordera, E Ibanez, E Gimeno, M Flowerdew, A Frew, K Davies, K Nambiar, R Rye, D Lambert, R Chowdhry, R Varghese, A Murray, L S Robinson, C McPherson, A Beddoe, R Sarpong, A Kieliszkowska, S Grigoriadou, M-J Valda, G Boyapati, A Zdanaviciene, D Andrews, J Laffan, I Nasr, A Bellin, B Crone, C Evans, A Twumasi, C Mende, S Cleary, M Stanton, C Schaeffer, G Ghaffari, F Ishmael, E Rael, N Vernon, N Kalra, J Zaragoza-Buxo, V Reddy, L Buyantseva, A Fazzi, H Heisey, J A Brown, A Kane, M Sweigart, T Johnson, L Kosh, S Shaikh, M Scarupa, A Economides, M White, M Kaliner, S Persons, A Newman, M J Noonan, A Johnson, J Tucker, D Aguilar, K Murphy, B Berendts, K Klefas, S Merritt, P Bak, R Chambers, M Iandoli, M Canova, S Bednar, J Vetrano, M Crawford, S Poston, D Paige, K Fuqua, K Hale, H Combs, H Haggard, K Phillipson, W Soong, M Sikora, M Lemke, P Luthin, C Neal, E Gilbert, K Bradley, W Zhao, M Abdalgani, A M Irani, B Ward, A Perry, A Hill, S Twombly, C Witte, J Rud, S Levitch, T Vonasek, J Curl, K Silva, T Mostofi, C Doss, N Schultz, D McNeil, A Thornton, A Urbank, P Rancitelli, N Palecek, T Singletary, J Altman, E Soltero, K Soltero, D F Soteres, L M Webb, D K Walters, J A Allen, G N Salem, E De La Cruz, A Hafez, T J Tyma, L Endean, A Tolman, M Naggs, A Davis, J Nelson, M Parks, B Borts, J Blair, J Sun, Y Brown, B Daly, C Tanguilig, T Le, M Tutto, M Berg, M LeFebvre, M Mallari

Affiliation

¹ From Barts Health NHS Trust (H.L.) and St. John's Institute of Dermatology, Guy's Hospital (C.G.), London, and the Clinical Investigation and Research Unit, Royal Sussex County Hospital, Brighton (M.T.) - all in the United Kingdom; Ospedale Luigi Sacco-U.O. Medicina Generale, Milan (M.C.), and the Department of Internal Medicine, University of Catania, Catania (S.N.) - both in Italy; Department of Medicine and Pediatrics, Penn State Hershey Allergy, Asthma, and Immunology, Hershey (T. Craig), and CSL Behring, King of Prussia (D.B.-K., J.E., D.P.) - both in Pennsylvania; the Department of Dermatology, Johannes Gutenberg University Mainz, Mainz (K.B.), and CSL Behring, Marburg (H. Feuersenger, J.-P.L., T.M., I.P.) - both in Germany; Baker Allergy, Asthma and Dermatology Research Center, Portland, OR (J. Baker); Institute for Asthma and Allergy, Chevy Chase, MD (H.H.L.); Allergy and Immunology Unit, Chaim Sheba Medical Center, Tel Hashomer (A.R.), and Allergy and Immunology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv (S.K.) - both in Israel; Clinical Research Center of Alabama, Birmingham (J. Bonner, J.A.); Department of Internal Medicine, Allergy Section Cincinnati, University of Cincinnati College of Medicine, Cincinnati (J.A.B.), and Toledo Institute of Clinical Research, Toledo (S.M.R.) - both in Ohio; Allergy Asthma Research Associates Research Center, Dallas (W.R.L.); Hungarian Angioedema Center, Third Department of Internal Medicine, Semmelweis University, Budapest (H. Farkas); the Department of Medicine, Immunology, and Allergy, Campbelltown Hospital, Campbelltown, NSW, Australia (C.H.K.); the Department of Clinical Immunology and Allergy, St. Michael's Hospital, Toronto (G.L.S.), Centre de Recherche Appliqué en Allergie de Québec, Quebec, QC (J.H.), McMaster University, Hamilton, ON (P.K.K.), Ottawa Allergy Research and University of Ottawa Medical School, Ottawa (W.Y.), and University of Alberta Hospital, Edmonton (B.R.) - all in Canada; Allergy and Asthma Clinical Research, Walnut Creek (J.J.), University of California, San Diego School of Medicine, La Jolla (M.R., B.L.Z.), and 705 W. La Veta Ave., Suite 101, Orange (D.S.L.) - all in California; Medical Research of Arizona, Scottsdale (M.E.M.); Hospital General Universitario Gregorio Marañón and Biomedical Research Network on Rare Diseases-U761, Institute for Health Research, Gregorio Marañón (M.L.B.), and the Allergy Department, Hospital La Paz Institute for Health Research, Biomedical Research Network on Rare Diseases (T. Caballero), Madrid, the Allergy Department, IIS Hospital Universitario La Fe, Valencia (M.D.H.), and Hospital Universitario Vall d'Hebron, Barcelona (M.G.) - all in Spain; Asthma and Allergy Association, Colorado Springs, CO (R.N.); Department of Internal Medicine, Virginia Commonwealth University, Richmond (L.B.S.); Spitalul Clinic Municipal, Cluj-Napoca, Romania (I.C.); Vital Prospects Clinical Research Institute, Tulsa, OK (I.H.); Institute of Clinical Immunology and Allergology, University Hospital, Hradec Kralove, Czech Republic (P.K.); Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston (A.B.); and Marycliff Allergy Specialists, Spokane, WA (R.G.G.).

PMID: 28328347
DOI: 10.1056/NEJMoa1613627

Abstract

Background: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks.

Methods: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks in a consecutive 2-month period within 3 months before screening. We randomly assigned the patients to one of four treatment sequences in a crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo, or vice versa. The primary efficacy end point was the number of attacks of angioedema. Secondary efficacy end points were the proportion of patients who had a response (≥50% reduction in the number of attacks with CSL830 as compared with placebo) and the number of times that rescue medication was used.

Results: Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI], -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P<0.001 for both comparisons). Response rates were 76% (95% CI, 62 to 87) in the 40-IU group and 90% (95% CI, 77 to 96) in the 60-IU group. The need for rescue medication was reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU group. Adverse events (most commonly mild and transient local site reactions) occurred in similar proportions of patients who received CSL830 and those who received placebo.

Conclusions: In patients with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly reduced the frequency of acute attacks. (Funded by CSL Behring; COMPACT EudraCT number, 2013-000916-10 , and ClinicalTrials.gov number, NCT01912456 .).

PubMed Disclaimer

Cited by

Edema of the Scrotum and Penile Shaft: An Uncommon Initial Presentation of Acquired Angioedema With Low C1-Inhibitor.
Matheny MV, Craig T, Clark JY. Matheny MV, et al. Case Rep Urol. 2024 Sep 11;2024:9172329. doi: 10.1155/2024/9172329. eCollection 2024. Case Rep Urol. 2024. PMID: 39295925 Free PMC article.
Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.
Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, Longhurst HJ, Radojicic C, Riedl MA. Bork K, et al. Allergy Asthma Clin Immunol. 2021 Apr 19;17(1):40. doi: 10.1186/s13223-021-00537-2. Allergy Asthma Clin Immunol. 2021. PMID: 33875020 Free PMC article. Review.
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. Levy DS, et al. Allergy Asthma Clin Immunol. 2020 Feb 4;16:8. doi: 10.1186/s13223-020-0409-3. eCollection 2020. Allergy Asthma Clin Immunol. 2020. PMID: 32042283 Free PMC article.
Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Beard N, et al. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article. Review.
Treatment of hereditary angioedema-single or multiple pathways to the rescue.
Valerieva A, Longhurst HJ. Valerieva A, et al. Front Allergy. 2022 Sep 12;3:952233. doi: 10.3389/falgy.2022.952233. eCollection 2022. Front Allergy. 2022. PMID: 36172291 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Collaborators

Affiliation

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Authors

Collaborators

Affiliation

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources